Interleukin-6 as a therapeutic target in human ovarian cancer.

ABSTRACT:

Purpose

We investigated whether inhibition of interleukin 6 (IL-6) has therapeutic activity in ovarian cancer via abrogation of a tumor-promoting cytokine network.

Experimental design

We combined preclinical and in silico experiments with a phase 2 clinical trial of the anti-IL-6 antibody siltuximab in patients with platinum-resistant ovarian cancer.

Results

Automated immunohistochemistry on tissue microarrays from 221 ovarian cancer cases showed that intensity of IL-6 staining in malignant cells significantly associated with poor prognosis. Treatment of ovarian cancer cells with siltuximab reduced constitutive cytokine and chemokine production and also inhibited IL-6 signaling, tumor growth, the tumor-associated macrophage infiltrate and angiogenesis in IL-6-producin

SUBMITTER: Coward J 

PROVIDER: S-EPMC3182554 | biostudies-literature | 2011 Sep

REPOSITORIES: biostudies-literature